Inmune Bio, Inc. INMB
Bio is a clinical-stage biotechnology company dedicated to developing and commercializing a pipeline of product candidates designed to
reprogram the innate immune system. Our mission is to address a broad range of diseases where chronic inflammation and immune dysfunction
are primary drivers of pathology.
Program: CORDStrom™ for RDEB Our primary focus is the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $50.0K | $14.0K | $155.0K | $374.0K | $181.0K | $11.0K | — | $0 | $0 | — |
| R&D | $20.7M | $33.2M | $20.3M | $17.1M | $20.5M | $5.9M | $3.3M | $3.4M | $435.4K | — |
| SG&A | $10.3M | $9.5M | $9.6M | $9.3M | $8.8M | $6.3M | $6.0M | $9.1M | $546.1K | — |
| Total operating expenses | $47.4M | $42.6M | $29.9M | $26.3M | $29.3M | $12.2M | $7.8M | $12.4M | $981.5K | — |
| Operating income | -$47.4M | -$42.6M | -$29.7M | -$26.0M | -$29.2M | -$12.2M | -$7.8M | -$12.4M | -$981.5K | — |
| Interest expense | — | $789.0K | $2.3M | $2.0M | — | — | — | — | — | — |
| Pre-tax income | $45.9M | $42.1M | $30.0M | — | — | — | — | -$12.4M | -$831.5K | — |
| Income tax | — | — | — | — | — | — | — | $0 | $0 | — |
| Net income | -$46.0M | -$42.0M | -$30.0M | -$27.3M | -$30.3M | -$12.1M | -$7.7M | -$12.4M | -$831.5K | — |
| EPS, basic | -1.86 | -2.11 | -1.67 | -1.52 | -1.88 | — | — | — | — | — |
| EPS, diluted | -1.86 | -2.11 | -1.67 | -1.52 | -1.88 | -1.01 | -0.75 | -1.43 | -0.13 | — |
| Shares, diluted (wtd. avg.) | $24.8M | $19.9M | $18.0M | $17.9M | $16.1M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $24.8M | $20.9M | $35.8M | $52.2M | $74.8M | $22.0M | $7.0M | $186.2K | $1.4M | $141.7K |
| Receivables | $4.3M | $1.2M | $1.9M | — | — | — | — | — | — | — |
| Total current assets | $29.9M | $22.7M | $39.9M | $64.7M | $82.6M | $24.0M | $7.8M | $849.3K | $1.9M | — |
| Property, plant and equipment | $955.0K | — | — | — | — | — | — | — | — | — |
| Other intangibles | — | $16.5M | $16.5M | $16.5M | $16.5M | $16.5M | $16.5M | $16.5M | $16.5M | — |
| Total assets | $32.4M | $39.6M | $57.0M | $81.8M | $99.9M | $40.7M | $24.5M | $17.4M | $18.4M | — |
| Accounts payable | $7.8M | $6.5M | $7.9M | $5.2M | $3.7M | $1.5M | $402.0K | $553.2K | $126.3K | — |
| Short-term debt | — | — | $9.9M | $5.0M | — | — | — | — | — | — |
| Total current liabilities | $8.4M | $7.2M | $18.5M | $10.9M | $4.4M | $1.8M | $700.4K | $823.8K | — | — |
| Long-term debt | — | $15.0M | — | $9.7M | $15.0M | — | — | — | — | — |
| Total liabilities | $8.8M | $7.5M | $18.9M | $21.7M | $19.7M | $1.9M | $860.5K | $823.8K | $309.7K | — |
| Retained earnings | -$209.0M | -$163.1M | -$121.0M | -$91.0M | -$63.7M | -$33.4M | -$21.3M | -$13.6M | -$1.2M | — |
| Total equity | $23.5M | $32.1M | $37.3M | $60.1M | $80.2M | $38.8M | $23.6M | $16.5M | $18.1M | -$149.2K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$22.6M | -$33.4M | -$12.0M | -$22.7M | -$28.5M | -$8.9M | -$5.4M | -$2.1M | -$761.8K | — |
| Depreciation and amortisation | $84.0K | — | — | — | — | — | — | — | — | — |
| Stock-based compensation | $9.9M | $7.6M | $7.4M | $7.1M | $4.8M | $3.1M | $4.1M | $10.0M | $199.6K | — |
| Capital expenditure | $1.0M | — | — | — | — | — | — | — | — | — |
| Investing cash flow | -$1.0M | — | — | — | -$15.0M | — | — | — | -$100.0K | — |
| Financing cash flow | $27.6M | $18.2M | -$4.2M | $729.0K | $96.4M | $23.9M | $12.2M | $900.0K | $2.1M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-047080.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $236.38B | 30.7x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $187.23B | 22.3x | 2.4% |
| MRNA | Moderna, Inc. | $58.11B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $45.01B | — | — |
| BIIB | BIOGEN INC. | $32.60B | 25.1x | 2.2% |
| SCNI | Scinai Immunotherapeutics Ltd. | $25.80B | — | 99.2% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $15.82B | 33.3x | 21.4% |
| EXEL | EXELIXIS, INC. | $14.62B | 21.2x | 7.0% |